JPH01246208A - External use preparation for skin - Google Patents
External use preparation for skinInfo
- Publication number
- JPH01246208A JPH01246208A JP63074217A JP7421788A JPH01246208A JP H01246208 A JPH01246208 A JP H01246208A JP 63074217 A JP63074217 A JP 63074217A JP 7421788 A JP7421788 A JP 7421788A JP H01246208 A JPH01246208 A JP H01246208A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- thymus
- vitamins
- deproteinized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 36
- 210000001541 thymus gland Anatomy 0.000 claims abstract description 25
- 229940088594 vitamin Drugs 0.000 claims abstract description 14
- 229930003231 vitamin Natural products 0.000 claims abstract description 14
- 235000013343 vitamin Nutrition 0.000 claims abstract description 14
- 239000011782 vitamin Substances 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 abstract description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 12
- 206010013786 Dry skin Diseases 0.000 abstract description 4
- 239000002674 ointment Substances 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 108091005804 Peptidases Proteins 0.000 abstract description 3
- 239000004365 Protease Substances 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 3
- 239000007853 buffer solution Substances 0.000 abstract description 3
- 230000029663 wound healing Effects 0.000 abstract description 3
- 150000007524 organic acids Chemical class 0.000 abstract description 2
- 230000007306 turnover Effects 0.000 abstract description 2
- 230000001133 acceleration Effects 0.000 abstract 1
- 239000008278 cosmetic cream Substances 0.000 abstract 1
- 239000008271 cosmetic emulsion Substances 0.000 abstract 1
- 239000008341 cosmetic lotion Substances 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000006210 lotion Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- -1 vitamin oil Chemical compound 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000008417 skin turnover Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GVJHHUAWPYXKBD-QLVXXPONSA-N (S,R,R)-alpha-tocopherol Chemical compound [H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C GVJHHUAWPYXKBD-QLVXXPONSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XDBMXUKHMOFBPJ-ZAFYKAAXSA-N L-ascorbic acid 2-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OS(O)(=O)=O)=C1O XDBMXUKHMOFBPJ-ZAFYKAAXSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 240000000042 Lilium speciosum Species 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- PAUSGZCRNOTKPK-UHFFFAOYSA-N [5-hydroxy-6-methyl-4-(octanoyloxymethyl)pyridin-3-yl]methyl octanoate Chemical compound CCCCCCCC(=O)OCC1=CN=C(C)C(O)=C1COC(=O)CCCCCCC PAUSGZCRNOTKPK-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940080284 cetyl sulfate Drugs 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は除蛋白胸腺抽出物と、ビタミン類の一種あるい
は二種以上とを配合することを特徴としてなる、肌荒れ
改善効果、角質改善効果、ターンオーバー速度促進効果
、創傷治癒促進効果に優れ、皮膚の老化を防止する効果
を有する皮膚外用剤に関する。[Detailed Description of the Invention] [Industrial Field of Application] The present invention is characterized by blending a deproteinized thymus extract with one or more vitamins, which has an effect on improving rough skin, an effect on improving keratin, The present invention relates to a skin preparation for external use that has excellent turnover rate promoting effects, wound healing promoting effects, and prevents skin aging.
[従来の技術]
荒れた肌は、乾燥して皮膚内の水分量が減少するととも
に角質細胞の機能が低下することなどによっておこる。[Prior Art] Rough skin is caused by dryness, a decrease in the amount of moisture in the skin, and a decline in the function of corneocytes.
特に冬期の空気が乾燥した時に悪化しやすく、このよう
な状態を改善する為には、皮膚のターンオーバーを高め
るとともに、皮膚機能を正常に維持することが必要であ
り、各種の薬剤が開発されてきた。It tends to worsen especially when the air is dry in winter, and to improve this condition, it is necessary to increase skin turnover and maintain normal skin function, and various drugs have been developed. It's here.
従来の方法としては、皮膚表面に皮脂類似組成物あるい
は保湿剤を塗布し、皮膚を被うことにより乾燥を防止し
たり、ビタミンE剤等により皮膚の血行を促進きせる方
法がとられてきたが、その効果はいまだ十分ではなく、
効果を期待するには、およばなかった。Conventional methods include applying sebum-like compositions or moisturizers to the skin surface and covering the skin to prevent dryness, and using vitamin E preparations to promote blood circulation in the skin. , its effect is still not sufficient,
The effect was not what I expected.
[発明が解決しようとする問題点]
本発明者らは、肌荒れ防止、肌荒れ改善効果を高め皮膚
の老化を防止する方法はないものかと鋭意研究した結果
、除蛋白胸腺抽出物とビタミン類の一種あるいは二種以
上とを併用することによって皮膚のターンオーバーを早
める作用が有ることを見出し、このことに着目して研究
した結果、除蛋白胸腺抽出物とビタミン類の一種あるい
は二種以上とを配合した皮膚外用剤を経皮的に投与した
場合、創傷治癒、肌荒れ防止、肌荒れ改善、老化防止の
効果に優れていることを見出し、本発明を完成するに至
った。[Problems to be Solved by the Invention] As a result of intensive research into a method to prevent skin aging by enhancing the effect of preventing and improving skin roughness, the present inventors found that a deproteinized thymus extract and a type of vitamin Alternatively, we found that the combination of two or more types has the effect of accelerating skin turnover, and as a result of research focusing on this, we combined deproteinized thymus extract and one or more vitamins. The present inventors have discovered that when administered transdermally, this external skin preparation has excellent effects on wound healing, prevention of rough skin, improvement of rough skin, and prevention of aging, and has led to the completion of the present invention.
[問題点を解決するための手段]
すなわち本発明は、除蛋白胸腺抽出物と、ビタミン類の
一種あるいは二種以上とを含有することを特徴とする皮
膚外用剤である。[Means for Solving the Problems] That is, the present invention is an external skin preparation characterized by containing a deproteinized thymus extract and one or more vitamins.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明に用いられる除蛋白胸腺抽出物は、例えば以下の
方法で得られる。The deproteinized thymus extract used in the present invention can be obtained, for example, by the following method.
動物由来の胸腺を細分もしくは均質化した後、−15℃
で脱脂を行ない、エーテル処理後、pH6,8〜7.9
の緩衝液を加え、更にpH3以下の有機酸を加えて分解
、抽出後、残渣にプロテアーゼを加え、粗エキスを得る
。この粗エキスを透析により除蛋白部と蛋白含有部とに
分離し、後者は濃縮又は凍結乾燥後、酵素によりベブタ
イド分画に至るまで加水分解し、酸・エタノール沈澱に
より残渣蛋白を除去し、先の除蛋白部と合わせ真空中で
1士しい乾燥残分含量になるまで濃縮し、pH7前後に
調節後無菌濾過して得られる。-15°C after mincing or homogenizing the animal-derived thymus
After degreasing with ether and treating with ether, pH 6.8-7.9
After adding a buffer solution and further adding an organic acid having a pH of 3 or less for decomposition and extraction, protease is added to the residue to obtain a crude extract. This crude extract is separated into a protein-free part and a protein-containing part by dialysis, and the latter is concentrated or freeze-dried, then hydrolyzed with enzymes to the bebutide fraction, residual protein is removed by acid/ethanol precipitation, and It is obtained by combining with the protein-removed portion of the product and concentrating in vacuo to a desired dry residue content, adjusting the pH to around 7, and then sterile filtration.
本発明に用いられる除蛋白胸腺抽出物の配合量は、皮膚
外用剤全量中乾燥固形分として0.0001〜5.0重
量%である。The amount of deproteinized thymus extract used in the present invention is 0.0001 to 5.0% by weight as a dry solid content in the total amount of the skin external preparation.
本発明においては、上記除蛋白胸腺抽出物に加えて、ビ
タミン類の一種あるいは二種以上を配合する。In the present invention, in addition to the above deproteinized thymus extract, one or more vitamins are blended.
本発明で用いられるビタミン類は、ビタミンへ油、レヂ
ノール、酢酸レチノール等のビタミンA類、リボフラビ
ン、酪酸リボフラビン、フラビンアデニンジヌクレオチ
ド等のビタミン82類、ピリドキシン塩酸塩、ビリドキ
シンジオクタノエート等のビタミン86類、L−アスコ
ルビン酸、L−アスコルビン酸シバルミチン酸エステル
、L−アスコルビン酸−2−硫酸Na等のビタミンC類
、パントテン酸カルシウム、D−バントテニルアルコー
ル、バントテニルエチルエーテル、アセデルバントテニ
ルエチルエーテル等のパントテン酸類、エルゴカルシフ
ェロール、コレカルシフェロール等のビタミンD類、ニ
コチン酸、ニコチン酸アミド、ニコチン酸ベンジル等の
ニコチン酸類、α−トコフェロール、酢酸トコフェロー
ル、ニコチンMDL−α−トコフェロール、コハク酸D
L−α−トコフェロール等のビタミンE類、ビタミンP
1ビオチン等がある。The vitamins used in the present invention include vitamin A such as vitamin oil, redinol, and retinol acetate, 82 vitamins such as riboflavin, riboflavin butyrate, and flavin adenine dinucleotide, and pyridoxine hydrochloride and pyridoxine dioctanoate. 86 vitamins, L-ascorbic acid, L-ascorbic acid cibalmitic acid ester, vitamin C such as L-ascorbic acid-2-sodium sulfate, calcium pantothenate, D-bantothenyl alcohol, bantothenyl ethyl ether, acederbant Pantothenic acids such as thenyl ethyl ether, vitamin Ds such as ergocalciferol and cholecalciferol, nicotinic acids such as nicotinic acid, nicotinamide, and benzyl nicotinate, α-tocopherol, tocopherol acetate, nicotine MDL-α-tocopherol, Succinic acid D
Vitamin E such as L-α-tocopherol, vitamin P
1 biotin, etc.
ビタミン類の配合量は、皮膚外用剤全量中の0゜000
1〜5.0重量%である。The amount of vitamins added is 0゜000 of the total amount of the skin external preparation.
It is 1 to 5.0% by weight.
除蛋白胸腺抽出物あるいはビタミンAの一種あるいは二
種以上の配合量が0.0001重景%未満ではその効果
が乏しくなる傾向があり、逆に5.0重量%を越えて配
合しても効果の大きな増大は望むことは出来ない。If the amount of deproteinized thymus extract or one or more types of vitamin A is less than 0.0001% by weight, the effect tends to be poor, and conversely, if the amount is more than 5.0% by weight, it will be effective. We cannot hope for a large increase in .
本発明の皮膚外用剤には上記した必須成分の他に通常化
粧品や医薬品等の皮膚外用剤に用いられる他の成分、例
えばアボガド油、パーム油、ビーナツツ油、牛脂、コメ
ヌカ油、ホホバ油、月見草油、カルナバロウ、ラノリン
、流動パラフィン、スクワラン、バルミチン酸イソステ
アリル、イソステアリルアルコール、トリー2−エチル
へキサン酸グリセリン等の油分、グリセリン、ソルビト
ール、ポリエチレングリコール、バチルアルコール、コ
ラーゲン、ヒアルロン酸、コンドロイチン硫酸、デキス
トラン硫酸ナトリウム等の保湿剤、バラジメチルアミノ
安息香酸アミル、2−ヒドロキシ−4−メトキシベンゾ
フェノン−5−スルホンMNa。In addition to the above-mentioned essential ingredients, the external skin preparation of the present invention contains other ingredients commonly used in external skin preparations such as cosmetics and pharmaceuticals, such as avocado oil, palm oil, peanut oil, beef tallow, rice bran oil, jojoba oil, and evening primrose. Oil, carnauba wax, lanolin, liquid paraffin, squalane, isostearyl valmitate, isostearyl alcohol, glycerin tri-2-ethylhexanoate, glycerin, sorbitol, polyethylene glycol, batyl alcohol, collagen, hyaluronic acid, chondroitin sulfate, Humectants such as dextran sodium sulfate, amyl valadimethylaminobenzoate, 2-hydroxy-4-methoxybenzophenone-5-sulfone MNa.
ウロカニン酸、ジイソブロビルケイヒ酸エチル等の紫外
線吸収剤、エリソルビン酸ナトリウム、パラヒドロキシ
アニソール等の酸化防止層、ステアリル硫酸ナトリウム
、セチル硫酸ジェタノールアミン、セチルトリメチルア
ンモニウムサッカリン、イソステアリン酸ポリエチレン
グリコール、アラキン酸グリセリル、ジグリセリンジイ
ソステアレート等の界面活性剤、エチルパラベン、ブチ
ルパラベン等の防腐剤、グリチルリチン酸誘導体、グリ
チルレチン酸誘導体、サリチル酸誘導体、ヒノキチオー
ル、酸化亜鉛、アラントイン等の消炎剤、胎盤抽出物、
グルタチオン、ユキノシタ抽出物等の美白剤、オウバク
、オウレン、シコン、シャクヤク、センブリ、バーチ、
セージ、ビワ、ニンジン、アロエ、ゼニアオイ、アイリ
ス、ブドウ、ヨクイニン、ヘチマ、ユリ、サフラン、セ
ンキュウ、シフウキヨウ、オトギリソウ、オノニス、ロ
ーズマリー、ニンニク等のf[tl 出物、ローヤルビ
リー、感光素、コレステロール語導体、各狸アミノ酸類
、牌臓抽出物、幼生血抽出物等の賦活剤、γ−オリザノ
ール等の血行促進剤、硫黄、チアントール等の抗脂漏剤
、カルボキシビニルポリマー、カリボキシメチルセルロ
ース、カルボキシヒト・ロキシプロビルセルロース等の
増粘剤、香料、水、アルコール、チタンイエロー、カー
サミン、ベニバナ赤等の色剤、ポリエチレン、ナイロン
等の樹脂粉末等を必要に応じて適宜配合することかでき
る。UV absorbers such as urocanic acid, ethyl diisobrobyl cinnamate, antioxidant layers such as sodium erythorbate and parahydroxyanisole, sodium stearyl sulfate, jetanolamine cetyl sulfate, cetyl trimethylammonium saccharin, polyethylene glycol isostearate, arachidic acid Surfactants such as glyceryl and diglycerine diisostearate, preservatives such as ethylparaben and butylparaben, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, anti-inflammatory agents such as hinokitiol, zinc oxide, allantoin, placenta extract,
Glutathione, whitening agents such as saxifrage extract, sagebrush, orensis, chicon, peony, japonica, birch,
Sage, loquat, carrot, aloe, mallow, iris, grape, Japanese lily, loofah, lily, saffron, nebula, perforatum, rosemary, garlic, etc., royal billy, photosensitizer, cholesterol word Conductors, various raccoon amino acids, activators such as spleen extract and larval blood extract, blood circulation promoters such as γ-oryzanol, antiseborrheic agents such as sulfur and thianthol, carboxyvinyl polymer, carboxymethylcellulose, carboxyhuman - Thickeners such as roxyprovir cellulose, fragrances, water, alcohol, coloring agents such as titanium yellow, casamine, safflower red, resin powders such as polyethylene and nylon, etc. can be appropriately blended as necessary.
また本発明の皮膚外用剤の剤型は任意であり、例えば化
粧水等の可溶化系、乳液、クリーム等の乳化系あるいは
軟膏、分散液などの剤型をとることができる。Further, the dosage form of the skin external preparation of the present invention is arbitrary, and may be, for example, a solubilized system such as a lotion, an emulsified system such as a milky lotion or a cream, or a dosage form such as an ointment or a dispersion.
[発明の効果コ
(ヒト皮膚による肌荒れ改善効果試験)実施例1で得た
化粧水とブランク化粧水(除蛋白胸腺抽出物及び酢酸ト
コフェロールを配合しないもの)を用いて人体パネルで
肌荒れ改善効果試験を行った。[Effects of the Invention (Skin improvement effect test on human skin) Skin roughness improvement effect test on human body panel using the lotion obtained in Example 1 and blank lotion (not containing deproteinized thymus extract and tocopherol acetate) I did it.
すなわち、女性健常人(顔面)の皮膚表面形態をミリス
ン樹脂によるレプリカ法を用いて肌のレプリカを取り題
?jlifm(17倍)にてH察する。皮紋の状態及び
角層のllJm状態から表−2に示す基準に基づいて肌
荒れ評価1.2と判断された者(肌あれパネル)25名
を用い、顔面左右半々に、実施例1で得た化粧水とブラ
ンク化粧水を1日1回2週間塗布した。In other words, the topic is to create a skin replica of the skin surface morphology of a healthy female person (facial) using the replica method using Millisne resin. Observe H using jlifm (17x magnification). Using 25 people (rough skin panel) who were judged to have a skin roughness rating of 1.2 based on the condition of the skin pattern and the llJm condition of the stratum corneum based on the criteria shown in Table 2, the test sample obtained in Example 1 was applied to the left and right half of the face. A blank lotion and a blank lotion were applied once a day for two weeks.
2週間後、再び上述のレプリカ法にて肌の状態を観察し
、表−1の判定基準に従って評価した。Two weeks later, the skin condition was observed again using the replica method described above and evaluated according to the criteria in Table 1.
(以下余白) 表−1 結果を表−2に示す。(Margin below) Table-1 The results are shown in Table-2.
表−2
この結果より、除蛋白胸腺抽出物及び酢酸トコフェロー
ル配合の化粧水を使用した顔面部位はブランク化粧水を
使用した顔面部位と比較し、顕著な肌荒れ改善効果が認
められた。Table 2 From the results, it was found that the facial area treated with the lotion containing deproteinized thymus extract and tocopherol acetate had a remarkable effect on improving rough skin compared to the facial area treated with the blank lotion.
[実施例]
次に実施例により本発明をざらに詳細に説明する。尚、
本発明はこれにより限定されるものではない。配合量は
重量%である。[Example] Next, the present invention will be explained in detail with reference to Examples. still,
The present invention is not limited thereby. The blending amount is in weight%.
実施例 1 化粧水
(1)除蛋白胸腺抽出物 0.05(2)酢
酸トコフェロール 0.01(3)グリセリン
4.0(4)1.3−ブチレングリ
コール 4.0(5)エタノール 7
.0(6)ポリオキシエチレン
オレイルアルコール 0.5
(7)メチルパラベン 0.05(8)ク
エン酸 0.05(9)クエン酸
ソーダ 0.1(10)香料
0.05(11)精製水
残余(製法)
精製水にクエン酸、クエン酸ソーダ、グリセリン、1.
3−ブチレングリコール、除蛋白胸腺抽出物を溶解する
。別にエタノールにポリオキシエヂレンオレイルアルコ
ール、酢酸トコフェロール、香料、メチルパラベンを溶
解し、これを前述の精製水溶液に加えて可溶化し、濾過
して化粧水を得た。Example 1 Lotion (1) Deproteinized thymus extract 0.05 (2) Tocopherol acetate 0.01 (3) Glycerin 4.0 (4) 1.3-butylene glycol 4.0 (5) Ethanol 7
.. 0 (6) Polyoxyethylene oleyl alcohol 0.5 (7) Methylparaben 0.05 (8) Citric acid 0.05 (9) Sodium citrate 0.1 (10) Fragrance
0.05 (11) Purified water
Residue (manufacturing method) Citric acid, sodium citrate, glycerin, purified water, 1.
3-Butylene glycol, dissolve the deproteinized thymus extract. Separately, polyoxyethylene oleyl alcohol, tocopherol acetate, fragrance, and methylparaben were dissolved in ethanol, and this was added to the above-mentioned purified aqueous solution to solubilize and filtered to obtain a lotion.
(除蛋白胸腺抽出物の製法)
子牛の胸腺を冷凍細分化し、アセトン501を加え48
時間放置し、序アセトン251を加え72時間放置し、
脂溶性部分を除去する。アセトン層を分離後、残留物に
エチルエーテル15L及び精製水5〜101を加え、−
15℃〜−25℃で100時間以上放置後、遠心分離を
行なう。残留物に緩衝液を加えて中性で2回分離抽出を
行ない(a、b)、残留物にクエン酸サイクルの酸1〜
8駕、並びに0.001〜0.01%の亜鉛を含む溶液
を加え、pH3以下で2回抽出する(c、d)。(Production method of protein-depleted thymus extract) Frozen calf thymus was cut into pieces, and acetone 501 was added to the
Leave it for an hour, add acetone 251 and leave it for 72 hours.
Remove fat-soluble parts. After separating the acetone layer, 15 L of ethyl ether and 5 to 10 liters of purified water were added to the residue, and -
After standing at 15°C to -25°C for 100 hours or more, centrifugation is performed. Add a buffer solution to the residue and perform separation and extraction twice in neutral conditions (a, b).
Add a solution containing 0.001% to 0.01% zinc and extract twice at pH 3 or lower (c, d).
残留物にプロテアーゼを加え48時間以上反応させ、更
にアルドン酸を加えて除蛋白する。更に、1〜2時間達
心分離した抽出物(e)と先に得られた抽出物a ”−
dを合わせ、パラベンを添加しpf(7,0に:A整し
た後、透析を行なう。その後無菌濾過し4℃で貯蔵する
(f)。蛋白含有部については冷凍乾燥ご酵素で加水分
解し除蛋白を行ない、遠心分離後、得られた除蛋白抽出
物gを、先の除蛋白抽出物fと合わせ濃縮し、防腐剤を
加え、PH調整後約10zの乾燥固型物を含有するまで
濃縮することにより得られる。Protease is added to the residue and reacted for 48 hours or more, and aldonic acid is further added to remove protein. Furthermore, the extract (e) separated for 1 to 2 hours and the previously obtained extract a''-
Combine d and add paraben to adjust pf (7.0:A), and then perform dialysis. After that, sterile filter and store at 4°C (f). Protein-containing parts are hydrolyzed with freeze-dried enzymes. After deproteinization and centrifugation, the resulting deproteinized extract g is concentrated with the previously deproteinized extract f, a preservative is added, and after pH adjustment, the mixture is concentrated until it contains dry solids of about 10z. Obtained by concentrating.
実施例 2 クリーム
(1)セトステアリルアルコール 3.5(2)ス
クワラン 40.0(3)ミツロウ
3.0(4)還元ラノリン
5.0(5)エチルパラベン
0.3(6)ポリオキシエチレン(20)
ソルビタンモノパルミチン酸
エステル 2.0(7)ステアリ
ン酸モノグリセリド 2.0(8)除蛋白胸腺抽出物
0.5実施例1記載の抽出物
(9)酢酸レチノール 2.0(10)
肝臓抽出物 0.01(11)月見
草油 0.05(12)香料
0.03(13)1.3−ブチ
レングリコール 5.0(14)グリセリン
5.0(15)精製水
残余(製法)
(1) (2) (3) (4) (5) (6) (
7)と(11) (12)を加熱溶解し75℃に加温し
た(8) (9) (10) (13) (14)と(
15)に攪拌しながら加える。ホモミキサー処理し乳化
粒子を細かくした後、攪拌しながら急冷し、クリームを
1また。Example 2 Cream (1) Cetostearyl alcohol 3.5 (2) Squalane 40.0 (3) Beeswax 3.0 (4) Reduced lanolin
5.0(5) Ethylparaben
0.3 (6) Polyoxyethylene (20) Sorbitan monopalmitate ester 2.0 (7) Stearic acid monoglyceride 2.0 (8) Deproteinized thymus extract 0.5 Extract described in Example 1 (9) Retinol acetate 2.0 (10)
Liver extract 0.01 (11) Evening primrose oil 0.05 (12) Flavoring
0.03(13) 1.3-butylene glycol 5.0(14) Glycerin
5.0 (15) Purified water
Residue (manufacturing method) (1) (2) (3) (4) (5) (6) (
7), (11), and (12) were dissolved by heating and heated to 75°C. (8), (9), (10), (13), (14),
Add to 15) while stirring. After processing with a homomixer to make the emulsified particles fine, it is rapidly cooled while stirring, and the cream is added once again.
実施例 3 乳液
(1)除蛋白胸腺抽出物 0.01実施例
1記載の抽出物
(2)L−アスコルビン酸−2−硫酸Na O,0
05(3)ステアリン酸 1.5(
4)セヂルアルコール 0.5(5)ミツ
ロウ 2.0(6)ポリオキシ
エチレン(10)
モノオレイン酸エステル 1.0
(7)クインスシード抽出物
(5%水溶液) 20.0
(8)ヒアルロン酸Ha O,1(9
)胎盤抽出物 0.05(10)プ
ロピレングリコール 5.0(11)エタノ
ール 3.0(12)エチルパラベ
ン 0.3(13)香11
0.03(14)精製水
残余(製法)
エタノールに香料を加えて溶解する(アルコール相)。Example 3 Emulsion (1) Deproteinized thymus extract 0.01 Extract described in Example 1 (2) L-ascorbic acid-2-sulfate Na O,0
05(3) Stearic acid 1.5(
4) Seedyl alcohol 0.5 (5) Beeswax 2.0 (6) Polyoxyethylene (10) Monooleic acid ester 1.0 (7) Quince seed extract (5% aqueous solution) 20.0 (8) Hyaluron Acid Ha O,1(9
) Placenta extract 0.05 (10) Propylene glycol 5.0 (11) Ethanol 3.0 (12) Ethylparaben 0.3 (13) Fragrance 11
0.03 (14) Purified water
Residue (manufacturing method) Add fragrance to ethanol and dissolve (alcohol phase).
精製水にプロピレングリコール、ヒアルロン酸Haを加
えて加熱溶解して70℃に保つ(水相)。クイスシード
抽出物を除く他の成分を混合し、加熱溶解して70℃に
保つ(油相)。水相に油イ目を加えて予備乳化を行ない
、ホモミキサーで均一に乳化する。これを攪拌しながら
アルコール相とクインスシード抽出物を加える。その後
攪拌しながら30℃に冷却して乳液を得た。Propylene glycol and hyaluronic acid Ha are added to purified water, dissolved by heating, and kept at 70°C (aqueous phase). The other ingredients except the Kuisseed extract are mixed, heated and dissolved and kept at 70°C (oil phase). Pre-emulsify by adding oil to the aqueous phase, and homogeneously emulsify using a homomixer. Add the alcohol phase and quince seed extract while stirring. Thereafter, the mixture was cooled to 30° C. while stirring to obtain a milky lotion.
実施例 4 パック
(1)除蛋白胸腺抽出物 0.05実施例1
記載の抽出物
(2)コレカルシフェロール 0.01(3)ポ
リビニルアルコール 15.0(4)ポリエチレン
グリコール 3.0(5)プロピレングリコール
7.0(6)エタノール 10.
0(7)メチルパラベン 0.05(8)
香1EI 0.05(9)精
製水 残余(製法)
精製水にポリエチレングリコール、プロピレングリコー
ル、メチルパラベン、除蛋白胸腺抽出物及びコレカルシ
フエa−ルを加え攪拌溶解する。Example 4 Pack (1) Deproteinized thymus extract 0.05 Example 1
Extract as described (2) Cholecalciferol 0.01 (3) Polyvinyl alcohol 15.0 (4) Polyethylene glycol 3.0 (5) Propylene glycol
7.0 (6) Ethanol 10.
0(7) Methylparaben 0.05(8)
Fragrance 1EI 0.05 (9) Purified water Remaining (manufacturing method) Add polyethylene glycol, propylene glycol, methyl paraben, deproteinized thymus extract, and cholecalcifera to purified water and dissolve with stirring.
つぎにポリビニルアルコールを加え沈黙攪拌し、香t1
を溶解したエタノールを加えI!拌溶解してパックを得
た。Next, add polyvinyl alcohol and stir silently.
Add ethanol dissolved in I! A pack was obtained by stirring and dissolving.
実施例 6 軟膏
(1)除蛋白胸腺抽出物 0.5実施例1記
戦の抽出物
(2)酢酸トコフェロール 1.0(3)パル
ミチン酸レゾノール 0.5(4)ステアリルアル
コール 18.0(5)モクロウ
20.0(6)ポリオキシエチレン(10)
モノオレイン酸エステル 0.25(7)グリセリ
ンモノ
ステアリン酸エステル 0.3
(8)ワセリン 40.0(9)精
製水 残余(製法)
精製水を70℃に保ち(水相)以下の成分を70℃にて
混合溶解する(油I■)。水相に油相を加え、ホモミキ
サーで均一に乳化後冷却して軟膏を得た。Example 6 Ointment (1) Deproteinized thymus extract 0.5 Example 1 Extract of the war (2) Tocopherol acetate 1.0 (3) Resonol palmitate 0.5 (4) Stearyl alcohol 18.0 (5 ) Mokuro
20.0 (6) Polyoxyethylene (10) Monooleate 0.25 (7) Glycerin monostearate 0.3 (8) Vaseline 40.0 (9) Purified water Remaining (manufacturing method) Purified water 70 Keep the temperature at 70°C (aqueous phase) and mix and dissolve the following ingredients at 70°C (oil I■). The oil phase was added to the water phase, uniformly emulsified using a homomixer, and then cooled to obtain an ointment.
特許出願人 株式会社 資生堂Patent applicant: Shiseido Co., Ltd.
Claims (1)
種以上とを含有することを特徴とする皮膚外用剤。1. A skin preparation for external use, characterized by containing a deproteinized thymus extract and one or more vitamins.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63074217A JPH01246208A (en) | 1988-03-28 | 1988-03-28 | External use preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63074217A JPH01246208A (en) | 1988-03-28 | 1988-03-28 | External use preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01246208A true JPH01246208A (en) | 1989-10-02 |
Family
ID=13540802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63074217A Pending JPH01246208A (en) | 1988-03-28 | 1988-03-28 | External use preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01246208A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001074A1 (en) * | 1992-07-13 | 1994-01-20 | Shiseido Company, Ltd. | Composition for dermatologic preparation |
US5686086A (en) * | 1992-07-13 | 1997-11-11 | Shiseido Co., Ltd. | External skin treatment composition |
US5798109A (en) * | 1992-07-13 | 1998-08-25 | Shiseido Company, Ltd. | External skin treatment composition |
US5962000A (en) * | 1992-07-13 | 1999-10-05 | Shiseido Company, Ltd. | External skin treatment composition |
JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
-
1988
- 1988-03-28 JP JP63074217A patent/JPH01246208A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001074A1 (en) * | 1992-07-13 | 1994-01-20 | Shiseido Company, Ltd. | Composition for dermatologic preparation |
US5484816A (en) * | 1992-07-13 | 1996-01-16 | Shiseido Company, Ltd. | External skin treatment composition |
US5686086A (en) * | 1992-07-13 | 1997-11-11 | Shiseido Co., Ltd. | External skin treatment composition |
US5798109A (en) * | 1992-07-13 | 1998-08-25 | Shiseido Company, Ltd. | External skin treatment composition |
US5962000A (en) * | 1992-07-13 | 1999-10-05 | Shiseido Company, Ltd. | External skin treatment composition |
US6024941A (en) * | 1992-07-13 | 2000-02-15 | Shiseido Company, Ltd. | External skin treatment composition |
KR100295030B1 (en) * | 1992-07-13 | 2001-09-17 | 겜마 아키라 | Skin external composition |
JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0601698B1 (en) | Topical composition comprising tocopherol | |
JPH05262636A (en) | Dermatic external preparation for body | |
JP2000229832A (en) | Skin lotion | |
JPH0873342A (en) | Skin external preparation or bathing agent containing rubi fructus extract | |
JP2003055190A (en) | Collagenase inhibitor and anti-ageing cosmetic | |
JP2001081008A (en) | Skin preparation for external use keeping and improving the skin from chapping | |
JPS5916816A (en) | Composition for external use | |
JP2002003358A (en) | Skin care preparation | |
JPS6379809A (en) | Skin drug for external use | |
JP3263409B2 (en) | External preparation for skin | |
JPH01246208A (en) | External use preparation for skin | |
JPH0782131A (en) | Hyaluronidase activity inhibitor and oil in water type cream base preparation | |
US5776438A (en) | External preparation | |
JPS61205204A (en) | External preparation for skin | |
JP3140876B2 (en) | Melanin production inhibitor and external preparation for skin | |
JPH10279418A (en) | Preparation for external use for skin | |
JP3076620B2 (en) | External preparation for skin | |
JPH11171784A (en) | External preparation for skin | |
JP2000063226A (en) | Skin preparation for external use | |
JPH10203921A (en) | Skin preparation for external use | |
JPS61254510A (en) | External agent for skin | |
JP2895525B2 (en) | External preparation for skin | |
DE1667890B2 (en) | DERMATOLOGICAL AND COSMETIC EXTERNAL PRODUCTS FOR THE TREATMENT OF SKIN COLLAGENOSE | |
JPH0210122B2 (en) | ||
JPH0436137B2 (en) |